DnB Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.4M Buy
31,427
+720
+2% +$245K 0.04% 298
2025
Q4
$12.2M Sell
30,707
-3,561
-10% -$1.58M 0.04% 257
2025
Q3
$15.6M Buy
34,268
+6,805
+25% +$2.77M 0.06% 219
2025
Q2
$8.96M Buy
27,463
+166
+0.6% +$45.9K 0.04% 282
2025
Q1
$7.37M Buy
27,297
+564
+2% +$145K 0.03% 307
2024
Q4
$6.29M Buy
26,733
+1,335
+5% +$351K 0.03% 344
2024
Q3
$6.99M Sell
25,398
-617
-2% -$161K 0.03% 327
2024
Q2
$6.32M Buy
26,015
+1,022
+4% +$161K 0.03% 308
2024
Q1
$3.74M Sell
24,993
-21,231
-46% -$3.54M 0.02% 402
2023
Q4
$8.85M Sell
46,224
-4,988
-10% -$850K 0.05% 261
2023
Q3
$9.07M Buy
51,212
+25,898
+102% +$4.94M 0.05% 243
2023
Q2
$4.81M Buy
25,314
+1,996
+9% +$396K 0.03% 362
2023
Q1
$4.67M Buy
23,318
+1,121
+5% +$236K 0.03% 381
2022
Q4
$5.28M Buy
22,197
+1,214
+6% +$259K 0.04% 340
2022
Q3
$4.2M Sell
20,983
-244
-1% -$46.5K 0.03% 360
2022
Q2
$3.1M Sell
21,227
-128
-0.6% -$18.2K 0.02% 436
2022
Q1
$3.49M Buy
21,355
+1,868
+10% +$285K 0.02% 449
2021
Q4
$3.3M Buy
19,487
+1,670
+9% +$310K 0.02% 461
2021
Q3
$3.36M Sell
17,817
-108
-0.6% -$20.3K 0.02% 427
2021
Q2
$3.04M Sell
17,925
-5,461
-23% -$800K 0.02% 463
2021
Q1
$3.3M Buy
23,386
+7,629
+48% +$1.15M 0.02% 425
2020
Q4
$2.05M Buy
15,757
+2,322
+17% +$310K 0.02% 459
2020
Q3
$1.96M Sell
13,435
-78
-0.6% -$11.1K 0.02% 405
2020
Q2
$2M Buy
13,513
+2,938
+28% +$396K 0.02% 386
2020
Q1
$1.15M Sell
10,575
-1,889
-15% -$218K 0.02% 459
2019
Q4
$1.44M Buy
12,464
+1,109
+10% +$111K 0.01% 520
2019
Q3
$913K Buy
+11,355
New +$898K 0.01% 559
2019
Q1
Sell
-10,261
Closed -$748K 626
2018
Q4
$748K Buy
10,261
+48
+0.5% +$3.69K 0.01% 556
2018
Q3
$894K Buy
+10,213
New +$1.03M 0.01% 549

Other funds holding ALNY